Skip to content

18th September 2023
Rare disease drug development needs regulatory incentives to grow in 2024
15th September 2023
What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?
21st July 2023
In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?
21st July 2023
How is an increased focus on patient-centric concerns influencing the way that you work?
16th March 2023
Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity
6th March 2023
BoB@JPM: Self-Replicating RNA With Elixirgen’s Akihiro Ko
2nd March 2023
A Next-Generation RNA Therapy Targets Telomere Disorders
2nd February 2023
Using Self-Replicating RNA Technology to Treat Telomere Biology Disorders with Akihiro Ko Elixirgen Therapeutics
31st January 2023
What do you view as the most disruptive or transformational technology or development on the horizon?
26th January 2023
Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration
Top